| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LAMP2 |
| Uniprot No | P13473 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-127aa |
| 氨基酸序列 | ELNLTDSENATCLYAKWQMNFTVRYETTNKTYKTVTISDHGTVTYNGSIC GDDQNGPKIAVQFGPGFSWIANFTKAASTYSIDSVSFSYNTGDNTTFP |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LAMP2重组蛋白的假设性参考文献示例(实际文献需通过学术数据库验证)：
---
1. **《Recombinant LAMP2 Protein Restores Autophagic Flux in Cellular Models of Danon Disease》**
- **作者**: Tanaka Y, et al.
- **摘要**: 研究通过重组LAMP2蛋白在Danon病细胞模型中的作用，证实其可恢复自噬溶酶体融合功能，改善异常代谢物积累。
2. **《Expression and Purification of Functional Human LAMP2 in a Mammalian Cell System》**
- **作者**: Eskelinen EL, et al.
- **摘要**: 描述利用哺乳动物细胞系统高效表达重组人LAMP2蛋白的方法，验证其与天然蛋白相似的糖基化修饰及溶酶体定位能力。
3. **《Structural Insights into LAMP2-Mediated Chaperone Activity Using Recombinant Protein》**
- **作者**: Cuervo AM, et al.
- **摘要**: 通过重组LAMP2蛋白的晶体结构分析，揭示其在分子伴侣介导的自噬(CMA)中识别底物蛋白的关键结构域。
4. **《Gene Therapy with Recombinant LAMP2B Rescues Cardiac Dysfunction in a Mouse Model of Danon Disease》**
- **作者**: Nishino I, et al.
- **摘要**: 利用腺相关病毒递送重组LAMP2B蛋白的基因疗法，显著改善Danon病小鼠模型的心肌功能并延长生存期。
---
**注意**：以上为基于LAMP2相关研究的示例性文献，实际引用请通过PubMed、Web of Science等平台检索最新论文，关键词建议：`"LAMP2 recombinant"`、`"LAMP2 autophagy"`、`"Danon disease therapy"`。
**Background of LAMP2 Recombinant Protein**
Lysosome-associated membrane protein 2 (LAMP2) is a key transmembrane glycoprotein predominantly localized in lysosomal and endosomal membranes. It plays critical roles in lysosomal biogenesis, autophagy, and cellular homeostasis by mediating vesicle trafficking, membrane stability, and lysosome-phagosome fusion. Structurally, LAMP2 consists of a heavily glycosylated luminal domain, a transmembrane region, and a short cytoplasmic tail that facilitates interactions with cytosolic proteins. Alternative splicing generates three isoforms (LAMP2A, LAMP2B, LAMP2C), each with distinct tissue-specific expression and functional roles.
LAMP2 is essential for chaperone-mediated autophagy (CMA), a selective degradation pathway where cytosolic proteins are translocated into lysosomes via LAMP2A-containing complexes. Dysregulation of LAMP2 is linked to severe pathologies. Mutations in the *LAMP2* gene cause Danon disease, an X-linked disorder characterized by cardiomyopathy, skeletal myopathy, and intellectual disability due to impaired autophagic flux and lysosomal dysfunction. Additionally, altered LAMP2 expression is implicated in cancer progression, neurodegenerative diseases (e.g., Alzheimer’s), and immune disorders.
Recombinant LAMP2 proteins are engineered to study its molecular mechanisms, develop therapeutic strategies, or serve as diagnostic tools. Produced via heterologous expression systems (e.g., mammalian, insect, or bacterial cells), recombinant LAMP2 retains functional domains for in vitro studies, such as protein interaction assays, autophagy modeling, or antibody production. Its applications include drug screening for lysosomal storage disorders, gene therapy validation for Danon disease, and exploring CMA modulation in age-related diseases. Ensuring proper post-translational modifications (e.g., glycosylation) during production is critical for maintaining its biological activity. Overall, LAMP2 recombinant proteins are vital for advancing lysosome-related research and therapeutic innovation.
×
